Thermo Fisher Scientific Inc. (NYSE: TMO), a global leader in serving science, demonstrated its robust financial health in the first quarter of 2024.
Despite a slight revenue decline of 3% to $10.34 billion from the previous year’s $10.71 billion, the company has shown a commendable increase in its GAAP diluted earnings per share (EPS), which grew by 4% to $3.46.
Furthermore, the adjusted EPS saw a 2% increase, reaching $5.11. This performance underscores Thermo Fisher’s ability to navigate the complexities of the market while continuing to deliver value to its stakeholders.
Significant achievements, including launching innovative products like the Thermo Scientific
Dionex Inuvion Ion Chromatography system and the Axiom PangenomiX Array marked the quarter. The company’s strategic capital deployment, highlighted by a $3.0 billion stock repurchase and an 11 percent dividend increase, reflects its strong financial position and confidence in future growth prospects.
Thermo Fisher Scientific Beats EPS and Revenue Expectations in Q1
When comparing these results against market expectations, Thermo Fisher has outperformed in several key areas. Analysts had projected an EPS of $4.71 and a revenue of $10.16 billion for the quarter. The company surpassed revenue expectations by reporting $10.34 billion and significantly exceeded the EPS forecast with an adjusted figure of $5.11.
The company’s ability to exceed analysts’ expectations indicates its robust commercial execution and operational discipline. Introducing high-impact, innovative products and expanding its service offerings have been crucial to this achievement.
TMO Ups Full-Year Revenue and Adjusted EPS Guidance for 2024
Thermo Fisher has raised its full-year revenue and adjusted EPS guidance for 2024, reflecting more robust operational performance. The company now expects revenue to be $42.3 to $43.3 billion, from the previous guidance of $42.1 to $43.3 billion.
Similarly, the adjusted EPS guidance has been raised to a new range of $21.14 to $22.02, up from the previous forecast of $20.95 to $22.00. This upward revision in guidance underscores the company’s confidence in its ability to continue delivering differentiated performance throughout the year.
Disclaimer: The author does not hold or have a position in any securities discussed in the article.
The post Thermo Fisher Scientific (TMO) Reports Q1 Beat with $5.11 EPS and $10.34 B in Revenue appeared first on Tokenist.
